Community Research Initiative (CRI) is an independent, nonprofit, community-based organization in New England dedicated to HIV and hepatitis C clinical research, treatment education, and financial assistance for approved HIV drug treatments and health insurance coverage.
This past month offered exciting news for people living with hepatitis C (HCV), thanks to your support of CRI's research. Gilead's all-oral single-tablet treatment for HCV, known as Harvoni, was recently approved by the FDA. The approval is supported by data from three Phase III studies, including the ION-3 trial, for which CRI was the enrolling site in Massachusetts. During ION-3, as many as 95% of participants were cured of HCV. Follow the link to read more about the ION-3 trial and other clinical trials at CRI.
HDAP staff, in collaboration with the Office of HIV/AIDS (OHA) of the Massachusetts Department of Public Health, have recently conducted two webinars to provide information on HDAP and the ACA, navigating the new MA Health Connector, and on special considerations for clients with HIV and their case managers. Click "Read More" to find out how to view these webinars.
Over 500 of you—riders, crew members, donors, supporters, and volunteers—gathered to make H2B's Ride Twelve an absolute success. On December 2, Harbor to the Bay presented CRI with a check for over $115k, and all because of your hard work and support. Thank you! Remember to save the date for Ride Thirteen: September 19, 2015.